PMID- 3911482
OWN - NLM
STAT- MEDLINE
DCOM- 19860317
LR  - 20071115
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 54
IP  - 4
DP  - 1985 Dec 17
TI  - A comparison between low molecular weight heparin (KABI 2165) and standard 
      heparin in the intravenous treatment of deep venous thrombosis.
PG  - 813-7
AB  - In order to study whether a low molecular weight heparin (LMWH) of mw 4000 D is 
      effective in the treatment of deep venous thrombosis (DVT), patients with DVT 
      verified by phlebography were randomized to treatment by continuous intravenous 
      infusion of either unfractionated heparin (UFH) or LMWH. The initial dose was 240 
      U (anti F Xa)/kg/12 h. This study (study I) was stopped because of major bleeding 
      in 2 newly operated patients in the LMWH group after 27 patients had been 
      treated. The heparin activity measured as F Xa inhibition assayed in retrospect, 
      was found to be much higher in the LMWH group (mean 1.6-2.0 anti F Xa U/ml) than 
      in the UFH group (mean 0.5-0.8 anti F Xa U/ml). A second study was therefore 
      initiated in which the DVT patients were randomly given UFH (240 U/kg/12 h) or 
      LMWH only 120 U (anti F Xa)/kg/12 h, as initial doses (study II). In this study 
      27 patients could be evaluated, the mean heparin activity still being higher in 
      the LMWH group (0.9-1.2 anti F Xa U/ml) than in the UFH group (0.5-0.7 anti F Xa 
      U/ml). A second phlebographic investigation showed progression of thrombus size 
      in 3 (11%) of the UFH patients of studies I and II (n = 29) and improvement in 14 
      (48%). There was no progression in any LMWH patient, 6 (50%) had improved in 
      study I and 10 (77%) in study II. The mean decrease of thrombus size score 
      (according to Marder) during treatment did not differ between the 3 
      groups.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Bratt, G
AU  - Bratt G
FAU - Tornebohm, E
AU  - Tornebohm E
FAU - Granqvist, S
AU  - Granqvist S
FAU - Aberg, W
AU  - Aberg W
FAU - Lockner, D
AU  - Lockner D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 9000-94-6 (Antithrombin III)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antithrombin III/metabolism
MH  - Bleeding Time
MH  - Blood Platelets/drug effects
MH  - Clinical Trials as Topic
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Heparin/adverse effects/*pharmacology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Random Allocation
MH  - Thrombophlebitis/blood/*drug therapy
EDAT- 1985/12/17 00:00
MHDA- 1985/12/17 00:01
CRDT- 1985/12/17 00:00
PHST- 1985/12/17 00:00 [pubmed]
PHST- 1985/12/17 00:01 [medline]
PHST- 1985/12/17 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1985 Dec 17;54(4):813-7.